Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Health
  • Artificial Intelligence
ncarol.com

Eve Wellness, a SF Breast Ultrasound Screening Clinic supports the recent FDA updates to the guidelines to inform women about breast density
ncarol.com/10215490

Trending...
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 119
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 108
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 107
Eve Wellness
Eve Wellness located in SF offers the first FDA-approved ultrasound screening technology specifically designed for detecting cancer in dense breast tissue.

SAN FRANCISCO - ncarol.com -- Eve Wellness, a San Francisco-based breast cancer screening clinic, is leading the charge in breast cancer screening by providing women the opportunity to get screened earlier, at any age, without a doctor referral, using their FDA-Approved GE ABUS ultrasound technology, powered by FDA-Approved AI (artificial intelligence), all without radiation. This comes on the heels of the FDA's new mandate, announced on March 9, 2023, requiring all mammography facilities to report breast density information and enhance communications with patients and providers.

The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."

More on ncarol.com
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
  • HIRO Ostomy Belt Launch by Richard O'Hamill

Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.

"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."

At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.

More on ncarol.com
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Lake Norman Philharmonic - Free Holiday Concert
  • S&P 500's 4.4% Plunge: Buy the Dip or Wait? KayeDinero Spotlights TrendSetter
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform

"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."

Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.

For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.

Contact
Brendan Foley
co-founder
MyEveWellness.com
***@myevewellness.com


Source: Eve Wellness, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Prince's Collaborator Shelby J To Be A Special Guest For "a Deadly Proposal" Red Carpet
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • 7th Annual RACE INDUSTRY WEEK Returns Nov. 30 – Dec. 3 With Free Live Webinars From Racing Leaders
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
  • AQUALIS of Morrisville, NC, Acquires Full Circle Environmental of Garner, NC
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • Young Author Taraji Jones Surpasses 100 Amazon Book Sales
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • Nautical Advisory Shares Buyer Perspective in Forbes Agency Council Webinar for Agency Founders
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
_catLbl0 _catLbl1

Popular on ncarol.com

  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era - 260
  • Parade of Homes Winners Announced - 240
  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 185
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 180
  • LCM Company Explains Professional Upholstery Cleaning in Charlotte, NC - 163
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton - 125
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 119
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 115
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options - 113
  • UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology - 111

Similar on ncarol.com

  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute